Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

VKTX

Viking Therapeutics Inc

Jan 08 • 04:00PM ET

31.65

-0.73 -2.25 %

Healthcare • Biotechnology • USA • NASD

Peers: MDGL AKRO GLMD AKBA ATON ARDX BOLD TVRD EYPT KYNB

| Held by: VTI VB XBI VBK VXF SCHA IWR VHT IWD IWS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.12	Insider Own	2.83%	Shs Outstand	112.45M	Perf Week	-10.03%
Market Cap	3.58B	Forward P/E	-	EPS next Y	-3.75	Insider Trans	-12.95%	Shs Float	109.84M	Perf Month	-16.67%
Enterprise Value	2.86B	PEG	-	EPS next Q	-0.90	Inst Own	65.29%	Short Float	21.88%	Perf Quarter	-2.22%
Income	-237.39M	P/S	-	EPS this Y	-169.43%	Inst Trans	-3.19%	Short Ratio	6.57	Perf Half Y	1.15%
Sales	0.00M	P/B	4.99	EPS next Y	-37.85%	ROA	-28.31%	Short Interest	24.03M	Perf YTD	-10.03%
Book/sh	6.34	P/C	5.01	EPS next 5Y	-	ROE	-29.23%	52W High	43.15 -26.65%	Perf Year	-25.58%
Cash/sh	6.32	P/FCF	-	EPS past 3/5Y	-12.29% -23.00%	ROIC	-33.28%	52W Low	18.92 67.28%	Perf 3Y	271.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.41% 4.37%	Perf 5Y	462.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-126.16%	Oper. Margin	-	ATR (14)	1.71	Perf 10Y	774.31%
Dividend Ex-Date	-	Quick Ratio	28.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.07	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	28.34	EPS Q/Q	-259.40%	SMA20	-10.13%	Beta	0.75	Target Price	93.39
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-12.52%	Rel Volume	0.83	Prev Close	32.38
Employees	36	LT Debt/Eq	0.00	Earnings	Oct 22 AMC	SMA200	3.72%	Avg Volume	3.66M	Price	31.65
IPO	Apr 29, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.15% -	Trades		Volume	3,029,621	Change	-2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Initiated	Canaccord Genuity	Buy	$106
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$104
Apr-08-25	Initiated	Goldman	Neutral	$30
Feb-13-25	Initiated	Scotiabank	Sector Outperform	$102
Feb-07-25	Initiated	Citigroup	Neutral	$38
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy	$109
Nov-04-24	Reiterated	H.C. Wainwright	Buy	$90 → $102
Sep-11-24	Initiated	JP Morgan	Overweight	$80
Jun-27-24	Initiated	Morgan Stanley	Overweight	$105
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$115 → $116
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14

Show Previous Ratings

Today 08:38PM	Lightning Round: QXO is a buy, says Jim Cramer (CNBC TV)
09:30AM	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
07:00AM	Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PR Newswire)
Jan-07-26 07:00AM	Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer (PR Newswire)
Jan-06-26 09:41AM	Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026? (Zacks)
05:50PM	Loading…
Jan-05-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -9.26%
04:03PM	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks)
08:34AM	Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026? (Zacks)
Jan-02-26 09:01AM	Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III (Zacks)
Dec-31-25 09:15AM	2 Beaten-Down Stocks That Could Bounce Back in 2026 (Motley Fool)
08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-30-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Dec-29-25 02:34PM	This Small But Mighty Stock Could Surprise Investors in 2026 (Barchart)
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
05:45PM	Loading…
Dec-23-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:01PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? (Zacks)
08:58AM	Premarket Movers: Albemarle Gaining Momentum on Lithium Boom (24/7 Wall St.)
Dec-22-25 06:46PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
06:50AM	Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) (Insider Monkey)
Dec-18-25 01:13PM	Viking Therapeutics, Inc. (VKTX): A Bull Case Theory (Insider Monkey)
12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
09:53AM	Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share? (Zacks)
Dec-16-25 01:35PM	1 Bold Prediction for Viking Therapeutics in 2026 (Motley Fool)
10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Dec-15-25 11:11PM	Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development (Insider Monkey)
05:45PM	Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
04:30AM	Loading…
Dec-13-25 04:30AM	My Top 10 Stocks to Buy for 2026 (Motley Fool)
Dec-12-25 11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
07:44AM	This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street (Insider Monkey)
07:35AM	3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 (Motley Fool)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
07:10AM	Bullish Analysts Just Cant Quit Strategy Shares After 60% Rout (Bloomberg)
Dec-09-25 09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily) +8.92%
11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
Dec-03-25 09:26AM	Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? (Zacks)
Dec-02-25 12:28PM	LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website (Zacks)
Dec-01-25 09:26AM	VKTX Stock Rises 34% in Three Months: Here's What You Should Know (Zacks) -6.14%
Nov-29-25 01:08PM	Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating (Insider Monkey)
Nov-28-25 09:30AM	Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? (Zacks)
Nov-27-25 11:30AM	Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:24AM	Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy (Zacks)
08:15AM	Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 (Motley Fool)
Nov-26-25 10:45AM	NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes (Zacks)
Nov-25-25 04:05PM	Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-24-25 08:30AM	Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand? (Zacks)
08:19AM	Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps (Investor's Business Daily)
08:16AM	Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally (Zacks)
Nov-22-25 09:20AM	2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon (Motley Fool)
Nov-21-25 11:30AM	Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
04:31AM	3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential (Motley Fool)
Nov-20-25 11:30AM	VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug (Zacks)
Nov-19-25 04:22PM	Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win (Investor's Business Daily)
06:05AM	Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
02:55AM	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 (PR Newswire)
Nov-18-25 06:45AM	2 No-Brainer Healthcare Stocks to Buy Now (Motley Fool)
Nov-17-25 10:24AM	NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock? (Zacks)
Nov-14-25 08:53AM	Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance? (Zacks)
Nov-12-25 09:30AM	Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? (Zacks)
08:34AM	Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3? (Zacks)
Nov-11-25 10:08AM	Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.49%
Nov-10-25 08:19PM	William Blair Reiterates "Buy" Rating on Viking Therapeutics (VKTX) Following New VK2735 Data (Insider Monkey)
10:26AM	Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook? (Zacks)
04:45AM	2 Monster Stocks in the Making (Motley Fool)
Nov-09-25 06:55AM	Is There a Future for Viking Therapeutics? (Motley Fool)
Nov-07-25 10:44AM	LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs (Zacks)
08:02AM	The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. (Investor's Business Daily)
Nov-06-25 02:19PM	Jim Cramer Recommends Eli Lilly Over Viking Therapeutics (Insider Monkey)
07:05AM	Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek 2025 (PR Newswire)
Nov-05-25 05:15AM	Here's Why Shares in Viking Therapeutics Shot Higher in October (Motley Fool) +5.31%
Nov-04-25 11:17PM	Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer (CNBC TV)
08:10PM	Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. (Motley Fool)
04:05PM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
01:35PM	Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera (Barrons.com)
Nov-03-25 11:41AM	Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock? (Zacks) -5.46%
11:13AM	Viking Therapeutics Could Be Pharmas Next Big Buyout Target (24/7 Wall St.)
04:45AM	Prediction: The Next Eli Lilly Might Already Be Trading Under $50 (Motley Fool)
Nov-02-25 09:20AM	Should You Buy Viking Therapeutics Before Nov. 5? (Motley Fool)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
04:55AM	3 Promising Growth Stocks That Are Down Around 60% From Their Highs (Motley Fool)
Oct-30-25 10:40AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.) +8.38%
Oct-29-25 04:05PM	Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 (PR Newswire)
09:35AM	Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 09:30AM	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:05AM	Viking Therapeutics: High Risk, High Reward Play (MarketBeat)
Oct-23-25 04:13PM	Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies (Investor's Business Daily) +7.96%
02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
02:36PM	Here's Why This Obesity Drug Company's Share Price Soared Today (Motley Fool)
10:39AM	Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
09:55AM	How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results? (Zacks)
Oct-22-25 11:01PM	Viking Therapeutics Inc (VKTX) Q3 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
04:05PM	Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05 08:31 PM
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,405	409,190	Jan 05 08:31 PM
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05 08:28 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05 08:25 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05 08:25 PM
MARIANNA MANCINI	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,406		Jan 05 04:32 PM
GREG ZANTE	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,470		Jan 05 04:30 PM
BRIAN LIAN	Officer	Jan 05 '26	Proposed Sale	32.96	233,409	7,692,134		Jan 05 04:29 PM
MATTHEW W. FOEHR	Director	Jan 02 '26	Proposed Sale	35.11	16,000	561,694		Jan 02 04:46 PM
Mancini Marianna	Chief Operating Officer	Oct 28 '25	Sale	35.00	6,185	216,492	382,467	Oct 28 07:51 PM
Rowland Charles A Jr	Director	Oct 27 '25	Sale	35.57	60,000	2,134,278	30,000	Oct 28 07:49 PM
Lian Brian	President & CEO	Oct 28 '25	Sale	35.01	38,989	1,364,923	2,419,109	Oct 28 07:48 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '25	Sale	35.00	6,185	216,481	173,592	Oct 28 07:47 PM
GREG ZANTE	Officer	Oct 28 '25	Proposed Sale	35.01	6,185	216,531		Oct 28 04:34 PM
MARIANNA MANCINI	Officer	Oct 28 '25	Proposed Sale	35.00	6,185	216,492		Oct 28 04:32 PM
BRIAN LIAN	Officer	Oct 28 '25	Proposed Sale	35.01	38,989	1,364,923		Oct 28 04:27 PM
CHARLES A ROWLAND JR.	Director	Oct 27 '25	Proposed Sale	35.57	60,000	2,134,278		Oct 27 04:25 PM
Lian Brian	President & CEO	Jul 03 '25	Sale	27.80	26,889	747,633	2,388,014	Jul 03 03:31 PM
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03 03:31 PM
Mancini Marianna	Chief Operating Officer	Jul 03 '25	Sale	27.77	4,266	118,473	377,535	Jul 03 03:30 PM
GREG ZANTE	Officer	Jul 03 '25	Proposed Sale	27.76	4,266	118,428		Jul 03 01:07 PM
MARIANNA MANCINI	Officer	Jul 03 '25	Proposed Sale	27.77	4,266	118,473		Jul 03 01:05 PM
BRIAN LIAN	Officer	Jul 03 '25	Proposed Sale	27.80	26,889	747,633		Jul 03 01:01 PM
FOEHR MATTHEW W	Director	Apr 11 '25	Option Exercise	8.00	20,786	166,288	132,036	Apr 14 07:26 PM
Rouan Sarah Kathryn	Director	Mar 31 '25	Buy	24.15	1,240	29,943	1,240	Apr 02 06:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VKTX

Viking Therapeutics Inc

Upgrade your FINVIZ experience